Exports of Hungarian pharmaceutical companies still dominate with domestic sales only accounting for HUF 159 bln of the total, Ilku told the daily.
Despite the falling revenues, R&D costs are on the rise – reaching HUF 68 bln – which is problematic, as the pharmaceutical sector’s chief source of funding for R&D is profit. For further details on the pharmaceutical sector’s actual stance in Hungary check the latest issue of Budapest Business Journal.
Subscribe to the print edition of the Budapest Business Journal here.
Producing journalism that is worthy of the name is a costly business. For over 30 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
